Risk of thromboembolic events in atrial fibrillation with chronic kidney disease

Stroke

Volumn 46, Issue 1, 2015, Pages 157-163

  Zeng, Wu Tao ^a   Sun, Xiu Ting ^a   Tang, Kai ^a   Mei, Wei Yi ^a   Liu, Li Juan ^a   Xu, Qing ^a   Cheng, Yun Jiu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

atrial fibrillation; chronic kidney disease; ischemic stroke

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; IDRAPARINUX; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CHADS2 SCORE; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CONFIDENCE INTERVAL; DATA ANALYSIS; DISEASE ASSESSMENT; DISEASE SEVERITY; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; KIDNEY FUNCTION; MEDLINE; META ANALYSIS; PREDICTIVE VALUE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; STROKE PATIENT; SYSTEMATIC REVIEW; UNCERTAINTY; VENOUS THROMBOEMBOLISM; CHRONIC KIDNEY FAILURE; COMPLICATION; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; GLOMERULAR FILTRATION RATE; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOEMBOLISM;

EID: 84920381385     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.006881     Document Type: Article

References (44)

1. Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip G Y. Risk of stroke or systemic embolism in atrial fbrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke. 2013;44:1329-1336.
2. Kokubo Y, Nakamura S, Okamura T, Yoshimasa Y, Makino H, Watanabe M, et al. Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the Suita Study. Stroke. 2009;40:2674-2679.
3. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ. 2010;341:c4986.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
5. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al. Impact of proteinuria and glomerular fltration rate on risk of throm-boembolism in atrial fbrillation: the anticoagulation and risk factors in atrial fbrillation (ATRIA) study. Circulation. 2009;119:1363-1369.
6. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, et al. Chronic kidney disease and prevalent atrial fbrillation: the Chronic Renal Insuffciency Cohort (CRIC). Am Heart J. 2010;159:1102-1107.
7. Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan W, et al. Association of chronic kidney disease with atrial fbrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol. 2011;4:26-32.
8. Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, et al. Impact of age on the association between CKD and the risk of future coronary events. Am J Kidney Dis. 2014;64:375-382.
9. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fbrillation and renal failure: the Swedish Atrial Fibrillation Cohort study [publishead online ahead of print April 10, 2014]. Eur Heart J. doi: 10.1093/eurheartj/ehu139. http://eurheartj. oxfordjournals.org/content/early/2014/04/09/eurheartj.ehu139.long. Accessed July 4, 2014.
10. Reinecke H, Engelbertz C, Schäbitz WR. Preventing stroke in patients with chronic kidney disease and atrial fbrillation: beneft and risks of old and new oral anticoagulants. Stroke. 2013;44:2935-2941.
11. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JJ, Cigarroa JE, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fbrillation: executive summary: a report of the american college of Cardiology/American heart association task force on practice guidelines and the heart rhythm [published online ahead of print March 28, 2014]. Circulation. doi: 10.1161/CIR.0000000000000040. http://circ.ahajournals.org/content/early/2014/04/10/CIR.0000000000000040. long. Accessed July 4, 2014.
12. Furie KL, Goldstein LB, Albers GW, Khatri P, Neyens R, Turakhia MP, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvu-lar atrial fbrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:3442-3453.
13. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fbrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke. 2012;43:3298-3304.
14. Cheng YJ, Liu ZH, Yao FJ, Zeng WT, Zheng DD, Dong YG, et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med. 2013;10:e1001515.
15. Cheng YJ, Zhang J, Li WJ, Lin XX, Zeng WT, Tang K, et al. More favorable response to cardiac resynchronization therapy in women than in men [published online ahead of print August 21, 2014]. Circ Arrhythm Electrophysiol. doi: 10.1161/CIRCEP.113.001786. http://circep.aha-journals.org/content/early/2014/08/20/CIRCEP.113.001786.long. Accessed September 20, 2014.
16. Cheng YJ, Yao FJ, Liu LJ, Tang K, Lin XX, Li WJ, et al. B-type natri-uretic peptide and prognosis of end-stage renal disease: a meta-analysis. PLoS One. 2013;8:e79302.
17. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, et al. Effcacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fbril-lation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129:961-970.
18. Nakagawa K, Hirai T, Takashima S, Fukuda N, Ohara K, Sasahara E, et al. Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fbrillation. Am J Cardiol. 2011;107:912-916.
19. Roldán V, Marín F, Manzano-Fernandez S, Fernández H, Gallego P, Valdés M, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratifcation risk scores for atrial fbrillation? Thromb Haemost. 2013;109:956-960.
20. Lin WY, Lin YJ, Chung FP, Chao TF, Liao JN, Chang SL, et al. Impact of renal dysfunction on clinical outcome in patients with low risk of atrial fbrillation. Circ J. 2014;78:853-858.
21. Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fbrillation. JAMA. 2014;311:919-928.
22. Gorin L, Fauchier L, Nonin E, Charbonnier B, Babuty D, Lip GY. Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fbrillation and atrial futter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest. 2011;140:911-917.
23. Guo Y, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, et al. Relation of renal dysfunction to the increased risk of stroke and death in female patients with atrial fbrillation. Int J Cardiol. 2013;168:1502-1508.
24. Chao TF, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, et al. R2CHADS2 score and thromboembolic events after catheter ablation of atrial fbril-lation in comparison with the CHA2DS2-VASc score. Can J Cardiol. 2014;30:405-412.
25. Kornej J, Hindricks G, Kosiuk J, Arya A, Sommer P, Husser D, et al. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fbrillation: the Leipzig Heart Center AF Ablation Registry. Circ Arrhythm Electrophysiol. 2013;6:868-874.
26. Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, et al. Stroke and bleeding in atrial fbrillation with chronic kidney disease. N Engl J Med. 2012;367:625-635.
27. Lin LY, Lee CH, Yu CC, Tsai CT, Lai LP, Hwang JJ, et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fbrillation-a nation wide database analysis. Atherosclerosis. 2011;217:292-295.
28. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, et al. Effcacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fbrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821-2830.
29. Uchiyama S, Hori M, Matsumoto M, Tanahashi N, Momomura S, Goto S, et al. Net clinical beneft of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fbrillation: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis. 2014;23:1142-1147.
30. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fbrillation: validation of the R(2) CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors in Atrial fbrillation) study cohorts. Circulation. 2013;127:224-232.
31. Apostolakis S, Guo Y, Lane DA, Buller H, Lip GY. Renal function and outcomes in anticoagulated patients with non-valvular atrial fbrillation: the AMADEUS trial. Eur Heart J. 2013;34:3572-3579.
32. Eikelboom JW, Connolly SJ, Gao P, Paolasso E, De Caterina R, Husted S, et al. Stroke risk and effcacy of apixaban in atrial fbrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis. 2012;21:429-435.
33. Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM, et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fbrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol. 2013;61:2079-2087.
34. 2-VASc score. Heart Rhythm. 2012;9:1755-1760.
35. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fbrillation: a report of the american college of Cardiology/American heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fbrillation): developed in collaboration with the european heart rhythm association and the heart rhythm society. Circulation. 2006;114:e257-e354.
36. Vázquez E, Sánchez-Perales C, Borrego F, Garcia-Cortés MJ, Lozano C, Guzmán M, et al. Infuence of atrial fbrillation on the morbido-mortality of patients on hemodialysis. Am Heart J. 2000;140:886-890.
37. Lip GY, Lim HS. Atrial fbrillation and stroke prevention. Lancet Neurol. 2007;6:981-993.
38. Reinecke H, Brand E, Mesters R, Schäbitz WR, Fisher M, Pavenstädt H, et al. Dilemmas in the management of atrial fbrillation in chronic kidney disease. J Am Soc Nephrol. 2009;20:705-711.
39. Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y, et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemo-dialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis. 1996;27:848-854.
40. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al. Elevations of infammatory and procoagulant biomarkers in elderly persons with renal insuffciency. Circulation. 2003;107:87-92.
41. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004;140:9-17.
42. Miyazaki-Anzai S, Masuda M, Demos-Davies KM, Keenan AL, Saunders SJ, Masuda R, et al. Endoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcifcation. J Am Heart Assoc. 2014;3:e000949.
43. Lip G Y. Chronic renal disease and stroke in atrial fbrillation: balancing the prevention of thromboembolism and bleeding risk. Europace. 2011;13:145-148.
44. Roldán V, Marín F, Fernández H, Manzano-Fernández S, Gallego P, Valdés M, et al. Renal impairment in a "real-life" cohort of anticoagu-lated patients with atrial fbrillation (implications for thromboembolism and bleeding). Am J Cardiol. 2013;111:1159-1164.